Abrogation of post-myeloablative chemotherapy neutropenia by ex-vivo expanded autologous CD34-positive cells.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 10509503.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We show that absolute and severe neutropenia after high-dose therapy with melphalan with or without total body irradiation can be abrogated by cells generated ex vivo. This may change the clinical practice of haematopoietic cell transplantation and high-dose chemotherapy because the morbidity and hospitalisation associated with neutropenia could be avoided or reduced.
Medical subject headings
- Antigens, CD34
- Antineoplastic Agents, Alkylating
- Hematopoietic Stem Cell Transplantation
- Melphalan
- Multiple Myeloma
- Neutropenia